Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2016

01-02-2016 | Review

Treating prolactinomas with dopamine agonists: always worth the gamble?

Authors: Sean Noronha, Victoria Stokes, Niki Karavitaki, Ashley Grossman

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.
Literature
1.
D. Maiter, V. Primeau, 2012 update in the treatment of prolactinomas. Ann. Endocrinol. 73, 90–98 (2012)CrossRef
2.
F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)CrossRef
3.
M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)CrossRefPubMed
4.
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society, Diagnosis and treatment of hyperprolactinaemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)CrossRefPubMed
5.
A.B. Moraes, C.M. Silva, L. Vieira Neto, M.R. Gadelha, Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. 79, 447–456 (2013)CrossRef
6.
B.M. Biller, M.E. Molitch, M.L. Vance, K.B. Cannistraro, K.R. Davis, J.A. Simons, J.R. Schoenfelder, A. Klibanski, Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338–2343 (1996)PubMed
7.
J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts, P. Petrossians, P. Coremans, C. Mahler, A. Stevenaert, J. Verlooy, C. Raftopoulos, A. Beckers, Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518–2522 (1999)CrossRefPubMed
8.
9.
Position statement on the use of dopamine agonists in endocrine disorders; Society for Endocrinology, Feb 2009 reviewed Nov 2011
10.
N. Herring, C. Szmigielski, H. Becher, N. Karavitaki, J.A. Wass, Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. 70, 104–108 (2009)CrossRef
11.
A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur. J. Endocrinol. 167, 17–25 (2012)CrossRefPubMed
12.
V. Delgado, N.R. Biermasz, S.W. van Thiel, S.H. Ewe, N.A. Marsan, E.R. Holman, R.A. Feelders, J.W. Smit, J.J. Bax, A.M. Pereira, Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2 year follow-up study. Eur. J. Endocrinol. 77, 99–105 (2012)
13.
R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169, 359–366 (2013)CrossRefPubMed
14.
R.S. Auriemma, R. Pivonello, L. Ferreri, P. Priscitelli, A. Colao, Cabergoline use for pituitary tumors and valvular disorders. Endocrinol. Metab. Clin. North Am. 44, 89–97 (2015)CrossRefPubMed
15.
H. Gu, S. Luck, P.V. Carroll, J. Powrie, J. Chambers, Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. 74, 608–610 (2011)CrossRef
16.
American Psychiatric Association (APA), Diagnostic and Statistical Manual of Mental Disorders—Text Revision (DSM-IV-TR) (APA, Washington, DC, 2000)CrossRef
17.
J. Ahlskog, Pathological behaviours provoked dopamine agonist therapy of Parkinson’s disease. Physiol. Behav. 104, 168–172 (2011)CrossRefPubMed
18.
P. Seeman, Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69, 183–189 (2015)CrossRefPubMed
19.
V.S. Premaratne, I. Saeger, B.K. Macdonald, Lesson of the month (1): cabergoline - ‘I eat funny on that’. Clin. Med. 14, 205–507 (2014)CrossRef
20.
J.R. Cornelius, M. Tippmann-Peikert, N.L. Slocumb, C.F. Frerichs, M.H. Silber, Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33, 81–87 (2010)PubMedPubMedCentral
21.
H.D. Weiss, L. Marsh, Impulse control disorders and compulsive behaviours associated with dopaminergic therapies in Parkinson’s disease. Neurol. Clin. Pract. 2, 267–274 (2012)CrossRefPubMedPubMedCentral
22.
A. Nevely, A. Frei, M. Graf, PO2-58: sexual misconduct induced by iatrogenic hyperprolactinaemia. Eur. Psychiatry 25, 678 (2010)CrossRef
23.
T.J. Moore, J. Glenmullen, D.R. Mattison, Reports of pathological gambling, hypersexuality and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174, 1930–1933 (2014)CrossRefPubMed
24.
Joint Formulary Committee, British National Formulary, 68th edn. (BMJ Group and Pharmaceutical Press, London, 2015)
25.
M. Davie, Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J. Neuropsychiatry Clin. Neurosci. 19, 473–474 (2007)CrossRefPubMed
26.
H. Falhammar, J.Y. Yarker, Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med. J. Aust. 190, 97 (2009)PubMed
27.
M. Gahr, B.J. Connemann, C.J. Schönfeldt-Lecuona, Pathological gambling induced by dopamine agonists. Fortschr. Neurol. Psychiatr. 79, 470–474 (2011)CrossRefPubMed
28.
S.K. Thondam, S. Alusi, K. O’Driscoll, C.E. Gilkes, D.J. Cuthbertson, C. Daousi, Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin. Neuropharmacol. 36, 170–172 (2013)CrossRefPubMed
29.
A. Gupta, R.S. Zimmerman, Hypersexuality in cabergoline-treated prolactinoma, 93rd Annual Meeting of the Endocrine Society: abstr. P3-312, 2011
30.
M.R. Nannenga, P.J. Tebben, T.B. Nippoldt, Development of impulse control disorders in patients with dopamine agonist-treated prolactinomas: a case series. 93rd Annual Meeting of the Endocrine Society: abstr. P3-311, 2011
31.
J. Martinkova, L. Trejbalova, M. Sasikova, J. Benetin, P. Valkovic, Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34, 179–181 (2011)CrossRefPubMed
32.
M.C. Viana, L.H. Andrade, Lifetime prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the Sao Paolo metropolitan area, Brazil: results from Sao Paolo Megacity Mental Health Survey. Rev. Bras. Psiquiatr. 34, 249–260 (2012)CrossRefPubMed
33.
M. Barake, A.E. Evins, L. Stoeckel, G.N. Pachas, L.B. Nachtigall, K.K. Miller, B.M. Biller, N.A. Tritos, A. Klibanski, Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17, 150–156 (2014)CrossRefPubMedPubMedCentral
34.
I. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: a case–control study. Clin. Endocrinol. 80, 863–868 (2014)CrossRef
35.
A.P. Athanasoulia, M. Ising, H. Pfister, C.S. Mantzoros, G.K. Stalla, C. Sievers, Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96, 204–211 (2012)CrossRefPubMed
Metadata
Title
Treating prolactinomas with dopamine agonists: always worth the gamble?
Authors
Sean Noronha
Victoria Stokes
Niki Karavitaki
Ashley Grossman
Publication date
01-02-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0727-2

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue

Endocrine Genetics/Epigenetics

Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome

Original Article

Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response

Viewpoint

Duration of anti-resorptive therapy for osteoporosis

Original Article

The bone-preserving effects of exendin-4 in ovariectomized rats

Original Article

Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma

Original Article

Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits